
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a leading multinational healthcare company that has a strong focus on providing personalized diagnosis and treatment of cancer through its proprietary genomic and molecular technologies. Despite recent challenges related to recoupment of previous payments and discontinuation of one of its tests, the company's core business is expected to continue growing at a steady pace with the potential for new partnerships and acquisitions. Additionally, the company's strong pipeline and focus on high-growth areas in the medical and life science tools sector make it a strong long-term investment opportunity.
Bears say
MDxHealth is facing challenges due to the discontinuation of sales for their Resolve UTI test, lowering their 2026 revenue guide and missing Q1 revenue and earnings expectations. This will require MDxHealth to rely on alternative growth drivers such as their ExoDx test and increased productivity from sales reps. The company has a low- to mid-teens revenue growth potential with expanding margins, but their recent financials raise concern and may require better execution from management for long-term success.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares